Summary:
In all, 18 patients (30–56 years; median 49) with MDS underwent allogeneic HSCT from related (n=12) or unrelated (n=6) donors after a conditioning regimen comprising thiotepa, cyclophosphamide, and TBI. GVHD prophylaxis consisted of cyclosporine (n=15) or tacrolimus (n=3) with short-course methotrexate. Four patients had low-risk disease (refractory anemia or complete remission after chemotherapy) and 14 patients had high-risk disease (RAEB, RAEB-t, or AML). Grade II–IV acute GVHD developed in six patients and chronic GVHD in 10. With a median follow-up of 31 months, the 2-year survival probability is 75% for low-risk patients and 57% for high-risk patients. One patient died of leukemia and six of treatment-related causes. This conditioning regimen requires further study in patients with MDS.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Luger S, Sacks N . Bone marrow transplantation for myelodysplastic syndrome – who? when? and which? Bone Marrow Transplant 2002; 30: 199–206.
Appelbaum FR, Anderson J . Allogeneic bone marrow transplantation for myelodysplastic syndrome: outcomes analysis according to IPSS score. Leukemia 1998; 12 (Suppl. 1): S25–S29.
Sierra J, Perez WS, Rozman C et al. Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia. Blood 2002; 100: 1997–2004.
Anderson JE . Allogeneic hematopoietic cell transplantation for myelodysplastic and myeloproliferative disorders. In: Thomas ED, Blume KG, Forman SJ (eds). Hematopoietic Cell Transplantation, 2 edn. Blackwell Scientific: Oxford, 1999; pp 872–886.
Zecca M, Pession A, Messina C et al. Total body irradiation, thiotepa, and cyclophosphamide as a conditioning regimen for children with acute lymphoblastic leukemia in first or second remission undergoing bone marrow transplantation with HLA-identical siblings. J Clin Oncol 1999; 17: 1838–1846.
Bearman SI, Appelbaum FR, Buckner CD et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 1988; 6: 1562–1568.
Glucksberg H, Storb R, Fefer A et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 1974; 18: 295–304.
Shulman HM, Sullivan KM, Weiden PL et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204–217.
Castagna L, Weshi EA, Bourhis JH et al. Successful donor lymphocyte infusion (DLI) in a patient with myelodysplastic syndrome (MDS) after failure of T-cell-depleted bone marrow transplantation (TD-BMT). Br J Hematol 1998; 103: 284–285.
Shiobara S, Nakao S, Ueda M et al. Donor leukocyte infusion for Japanese patients with relapsed leukemia after allogeneic bone marrow transplantation: lower incidence of acute graft-versus-host disease and improved outcome. Bone Marrow Transplant 2000; 26: 769–774.
Kroger N, Schetelig J, Zabelina T et al. A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome. Bone Marrow Transplant 2001; 28: 643–647.
Rezvani K, Lalancette M, Szydlo R et al. Non-myeloablative stem cell transplant in AML, ALL, and MDS: disappointing outcome for patients with advanced phase disease. Blood 2000; 96 (Suppl): 2061.
Locatelli F, Niemeyer C, Angelucci E et al. Allogeneic bone marrow transplantation for chronic myelomonocytic leukemia in childhood: a report from the European Working Group on myelodysplastic syndrome in childhood. J Clin Oncol 1997; 15: 566–573.
Ratannatharthorn V, Karanes C, Uberti J et al. Busulfan-based regimens and allogeneic bone marrow transplantation in patients with myelodysplastic syndromes. Blood 1993; 81: 2194–2199.
Anderson JE, Appelbaum FR, Schoch G et al. Allogeneic marrow transplantation for myelodisplastic syndrome with advanced disease morphology: a phase II study of buslfan, cyclophosphamide, and total body irradiation and analysis of prognostic factors. J Clin Oncol 1996; 14: 220–226.
Egorin MJ, Snyder SW, Pan SS et al. Cellular transport and accumulation of thiotepa in murine, human, and avian cells. Cancer Res 1989; 49: 5611–5617.
Egorin MJ, Snyder SW, Pan SS et al. Cellular transport and accumulation of thiotepa. Semin Oncol 1990; 17: 7–17.
Egorin MJ, Snyder SW, Wietharn BE et al. Effects of ethanolamine and choline on thiotepa cellular accumulation and cytotoxicity in L1210 cells. Cancer Res 1990; 50: 4322–4327.
Wolff SN, Herzig RH, Fay JW et al. High-dose N,N′,N″-triethylenthiophosphoramide(thiotepa) with autologous bone marrow transplantation: phase I studies. Semin Oncol 1990; 17 (Suppl. 3): 2–6.
Papadopoulos EB, Carabasi MH, Castro-Malaspina H et al. T-cell-depleted allogeneic bone marrow transplantation as postremission therapy for acute myelogenous leukemia: freedom from relapse in the absence of graft-versus-host disease. Blood 1998; 91: 1083–1090.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Fujimaki, K., Taguchi, J., Fujita, H. et al. Thiotepa/cyclophosphamide/TBI as a conditioning regimen for allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome. Bone Marrow Transplant 33, 789–792 (2004). https://doi.org/10.1038/sj.bmt.1704451
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1704451
Keywords
This article is cited by
-
Clinical significance of the administration of cytarabine or thiotepa in addition to total body irradiation and cyclophosphamide for allogeneic hematopoietic cell transplantation in patients with acute leukemia
International Journal of Hematology (2015)
-
Pretransplant serum ferritin is associated with bloodstream infections within 100 days of allogeneic stem cell transplantation for myeloid malignancies
International Journal of Hematology (2011)